David C. Francisco, born on April 1, 1964, has been the Chief Financial Officer of Organogenesis Holdings Inc. since February 2021. He brings over 20 years of experience from PerkinElmer, where he held various leadership roles, including Vice President and...

David C. Francisco, born on April 1, 1964, has been the Chief Financial Officer of Organogenesis Holdings Inc. since February 2021. He brings over 20 years of experience from PerkinElmer, where he held various leadership roles, including Vice President and Treasurer. His academic background includes an M.B.A. in Finance from Bentley College and a B.S. in Industrial Engineering from UMass Amherst, showing he has a solid grip on both finance and operations. In 2023, David's total compensation rose to $1.62 million, fueled by his strong performance metrics that focus on net revenue and gross margins. His stock options and bonuses reflect the company’s growth, indicating his financial decisions are directly tied to the company’s performance. David manages a significant ownership stake in Organogenesis, showcasing his commitment to the firm’s future. His broad financial expertise and strategic outlook help steer the company in a competitive landscape.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Organogenesis Holdings Inc. CEOs

O

David C. Francisco

CEO of Organogenesis Holdings Inc.

Education

M.B.A. in Finance from Bentley College

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

April 1, 1964 - 61 years ago

CEO of Organogenesis Holdings Inc. for

4 years 2 months (Feb 2021 - Present)

Previous Experience

Chief Financial Officer of Organogenesis Holdings Inc.

Rivals

Competitors/colleagues of David C. Francisco

Holdings

See how much did David C. Francisco make over time.

As Chief Financial Officer at Organogenesis Holdings Inc., David C. Francisco has a notable position in the company, holding many shares and options. In 2023, he had stock awards amounting to over 12,800 shares that vested, highlighting the importance of...

As Chief Financial Officer at Organogenesis Holdings Inc., David C. Francisco has a notable position in the company, holding many shares and options. In 2023, he had stock awards amounting to over 12,800 shares that vested, highlighting the importance of stock options in his total earnings. His holdings reflect a significant tie to the company’s stock performance – showing strong belief in Organogenesis. He also managed stock options worth about $287,892, which can be exercised over four years. His wealth fluctuates based on the company's performance, emphasizing his long-term commitment to its success. David's most substantial growth in stock holdings occurred from 2021 to today, aligning with his rising responsibilities and compensation.

Insider Trading

See recent insider trades of David C. Francisco.

ORGO

165,156 shares

ORGO

Feb 19, 2025

Received

ORGO

160,350 shares

ORGO

Feb 21, 2024

Received

ORGO

242,508 shares

ORGO

Feb 22, 2023

Received

ORGO

40,348 shares

ORGO

Feb 15, 2022

Received

ORGO

10,965 shares

ORGO

Feb 16, 2021

Received

ORGO

5,396 shares

ORGO

Feb 15, 2021

Received

Compensation History

See how much did David C. Francisco make over time.

In 2023, David C. Francisco’s total compensation reached $1,622,944, reflecting a substantial increase from 2022’s $1,185,811. His salary was $419,930, with a cash bonus of $160,902 based on the company's performance metrics. David received vested stock worth nearly $36,995. He also had stock grants totaling over $242,508, which will vest over four years. This compensation package aligns incentives between David and company performance, as much of his earnings tie back to how well Organogenesis does. The focus on performance metrics like net revenue and gross margins makes it clear that David is not just a leader; he’s invested in the company's financial health.

Year

2023

Total Compensation

$665.51K

Salary

$419.93K

Board Justification

The compensation philosophy aims to align executive compensation with business objectives, individual performance, and stockholder interests, ensuring competitive compensation to attract and retain top talent.

Bonus

$160.90K

Board Justification

The cash bonus for fiscal year 2023 was based on the achievement of corporate performance metrics, with a target percentage of 60% of base salary, resulting in a payment of approximately 65% of the target bonus.

Other

$47.69K

Board Justification

Other compensation includes benefits such as a leased automobile, tax gross-ups, life insurance, long-term disability insurance, and 401(k) contributions.

Restricted Stock

$37.00K(12.84K RSU)

Board Justification

The stock awards that vested in 2023 were based on prior grants, with a total of 12,829 shares vesting during the year.

Performance Metrics

The performance metrics for determining the compensation included net revenue, gross margin percentage, and Adjusted EBITDA.

Other Organogenesis Holdings Inc. CEOs

Here are other CEOs of Organogenesis Holdings Inc.

Gary S. Gillheeny, Sr.

Ex-CEO of Organogenesis Holdings Inc.

December 2018 - May 2021